MTX61 is a novel SĀPH™ conjugate of a proangiogenic compound for treatment of peripheral artery disease. Under development at Matrx, this new drug will address an underserved $8B market for peripheral artery disease affecting over 8 million patients worldwide. MTX61 is designed as a long-term, intramuscular injection for generation of new blood vessels in the affected area